Curtis JR et al. – The rate of hip fracture was increased among women compliant with bisphosphonate therapy for 2 years who subsequently discontinued, suggesting that discontinuation is not advisable under these conditions. Methods
Study to evaluate the risk of hip fracture after bisphosphonate discontinuation in older women compliant with bisphosphonates >=2 yrs
Using administrative databases from a large U.S. healthcare organization, women initiating bisphosphonate therapy compliant for 2 yrs were identified
Rate of hip fracture among women who discontinued bisphosphonates vs those who remained on therapy were examined
Results
At 2 yrs, 9,063 women were eligible for analysis
Hip fracture incidence among women who discontinued bisphosphonates vs those who did not was 8.43 vs 4.67 per 1000 person yrs
The adjusted hazard ratio of hip fracture per 90 days following discontinuation was 1.2
For women with higher compliance at 2 yrs or compliant for 3 yrs, there were no differences in risk associated with discontinuation
See all
